In conclusion, SLC7A11 could be a potential therapeutic target in ovarian cancer since it plays a key role in improving cancer cells’ response to chemotherapeutic agents in both sensitive and resistant ovarian cancer cells. This evidence concerns the gene SLC7A11 and cancer.